南京普爱医疗设备股份有限公司近日向港交所递交招股书。对比过往财务数据,公司2022年至2024年连续三年亏损累计1.04亿元,核心产品移动式C形臂X射线机出现量价齐跌。同时,高额销售费用及研发投入转化效率不足成为业绩下滑主因。此外,公司存在长达17年的股权代持问题,前保荐机构华龙证券通过协议获得“旱涝保收”保障,进一步引发市场对公司治理结构的担忧。免责声明:本文内容由开放的智能模型自动生成,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.